Table 3A.

Changes in IBAT mRNA Expression Following SC OT and CL 316243 Treatment in Male DIO Rats

SC Treatment	VEH/VEH	OT/VEH	VEH/CL 316243	OT/CL 316243
IBAT
Adrb1	1.0 ± 0.3	1.0 ± 0.1	0.8 ± 0.1	0.9 ± 0.4
Adrb3	1.0 ± 0.1	0.9 ± 0.2	0.5 ± 0.1*	0.5 ± 0.04*
Ucp1	1.0 ± 0.1	1.0 ± 0.1	1.6 ± 0.1*	1.6 ± 0.1*
Cidea	1.0 ± 0.1	1.0 ± 0.1	1.0± 0.1	0.9 ± 0.1
Dio2	1.0 ± 0.1	1.5 ± 0.2	3.3 ± 0.4*	3.5 ± 0.3*
Gpr120	1.0 ± 0.2	0.9 ± 0.2	19.8 ± 2.4*	15.9 ± 2.1*
Prdm16	1.0 ± 0.1	0.9 ± 0.1	0.8 ± 0.1	0.9 ± 0.1
Ppargc1a	1.0 ± 0.05	1.0 ± 0.2	4.8 ± 0.4*	5.9 ± 0.5*

IBAT was collected in 6-h fasted rats at 2-h post-injection of vehicle or CL 316243 (0.5 mg/kg)

^*P <0.05 vs vehicle

N=10–12/group